Fisher Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $24.9M | Sell |
2,782,489
-269,648
| -9% | -$2.42M | 0.01% | 291 |
|
|
2025
Q1 | $22.9M | Sell |
3,052,137
-130,480
| -4% | -$979K | 0.01% | 309 |
|
|
2024
Q4 | $23.9M | Sell |
3,182,617
-155,445
| -5% | -$1.17M | 0.01% | 326 |
|
|
2024
Q3 | $25.4M | Buy |
3,338,062
+481,359
| +17% | +$3.66M | 0.01% | 311 |
|
|
2024
Q2 | $17.7M | Sell |
2,856,703
-27,916
| -1% | -$173K | 0.01% | 353 |
|
|
2024
Q1 | $14.7M | Buy |
2,884,619
+50
| +0% | +$254 | 0.01% | 370 |
|
|
2023
Q4 | $17.3M | Sell |
2,884,569
-300,630
| -9% | -$1.8M | 0.01% | 346 |
|
|
2023
Q3 | $22.6M | Sell |
3,185,199
-1,139,354
| -26% | -$8.07M | 0.01% | 335 |
|
|
2023
Q2 | $30.4M | Buy |
4,324,553
+31,157
| +0.7% | +$219K | 0.02% | 318 |
|
|
2023
Q1 | $35.8M | Sell |
4,293,396
-137,718
| -3% | -$1.15M | 0.02% | 288 |
|
|
2022
Q4 | $50.9M | Sell |
4,431,114
-732,731
| -14% | -$8.41M | 0.03% | 240 |
|
|
2022
Q3 | $65.1M | Sell |
5,163,845
-52,984
| -1% | -$668K | 0.05% | 213 |
|
|
2022
Q2 | $55.2M | Buy |
5,216,829
+1,230,006
| +31% | +$13M | 0.04% | 213 |
|
|
2022
Q1 | $64.8M | Sell |
3,986,823
-110,229
| -3% | -$1.79M | 0.04% | 215 |
|
|
2021
Q4 | $56.7M | Buy |
4,097,052
+1,091,430
| +36% | +$15.1M | 0.03% | 233 |
|
|
2021
Q3 | $43.2M | Buy |
3,005,622
+994,391
| +49% | +$14.3M | 0.03% | 247 |
|
|
2021
Q2 | $31.8M | Buy |
+2,011,231
| New | +$31.8M | 0.02% | 276 |
|